Use of brolucizumab in macular degeneration

Brolucizumab is a medication that is used in the treatment of macular degeneration, specifically neovascular (wet) age-related macular degeneration (AMD). Macular degeneration is a progressive eye disease that affects the central part of the retina called the macula, leading to gradual vision loss.

Brolucizumab belongs to a class of medications known as anti-vascular endothelial growth factor (anti-VEGF) agents. It works by inhibiting the activity of VEGF, a protein that stimulates abnormal blood vessel growth in the retina. These abnormal blood vessels can leak fluid, blood, and other substances, leading to macular edema and scarring, which further impairs vision.

By inhibiting VEGF, brolucizumab helps reduce the growth of these abnormal blood vessels, and minimizes fluid leakage and inflammation in the macula. This can help preserve vision and potentially even improve vision in some cases.

Brolucizumab is administered via intravitreal injection, which means it is injected directly into the eye. It is typically given every 8 to 12 weeks, depending on the patient's response to treatment. The frequency of injections may vary among individuals, and it is usually determined by the ophthalmologist based on the patient's specific condition.

In clinical trials, brolucizumab has demonstrated efficacy in improving visual acuity and reducing macular edema in patients with neovascular AMD. It has also shown non-inferiority and superior durability compared to other anti-VEGF agents commonly used in the treatment of this condition, such as ranibizumab and aflibercept.

However, like any medication, brolucizumab may have side effects. These can include eye pain, increased intraocular pressure, inflammation in the eye, floaters, and in rare cases, retinal detachment. It is important for patients to communicate any symptoms or changes in vision to their ophthalmologist promptly.

Overall, brolucizumab is a newer treatment option for neovascular AMD that has shown promising results in clinical trials. It has the potential to provide effective and durable outcomes in the management of this sight-threatening condition. However, the specific use and dosage of brolucizumab should be determined by a qualified healthcare professional based on individual patient characteristics and needs.